In 2013, we first reported the aberrant upregulation of CBS in human colon tumor tissue and colon cancer-derived cell lines and demonstrated that inhibition of CBS expression and/or activity had antitumor effects [16]. This evidence concerns the gene CBS and malignant colon neoplasm.